pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Apr 28·1 min read
save

Experts warn brain-health initiatives overlook mental illness

Apr 28, 2026·read at STAT ↗Negative

The authors – a professor at Oxford and Yale, the dean of Mount Sinai’s medical school, and a former U.S. congressman – argue that the surge in funding for neuroscience is being directed mainly toward neurodegenerative diseases, leaving mental illness on the sidelines.

They contend that this split between neurological disorders and mental health is both a scientific misstep and a strategic loss, reducing the potential benefits of a truly inclusive "brain health" agenda.

While governments, industry and philanthropies are investing heavily to extend healthy cognitive life, the authors call for the same early‑screening and preventive mindset that drives cancer and heart‑health programs to be applied to mental illness as well.

The piece warns that ignoring mental health in the brain‑health conversation risks wasting human potential and undermines the broader goal of reducing the overall burden of brain disease.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: Why do discussions about ‘brain health’ ignore mental illness?”

read at STAT ↗
1,713 words · retrieved Apr 30
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Boundless Bio, Inc.LEADINGNational Institutes of Health
drugs
Novel Therapeutic
topics
Psychiatry & CNS13Alzheimer's Disease8Neurology8Major Depression7Cardiology5Oncology4Schizophrenia3HematologyHypertensionMultiple SclerosisType 2 Diabetes

related stories

  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • 4d agoGSK laying off 1.2K+ in BelgiumBioSpace
  • Jul 18Opinion: STAT readers on the value of primary care, obesity as a disease, and moreSTAT
  • Jul 1412 ideas for tackling the U.S. alcohol epidemicSTAT
  • Jun 6Opinion: How the Amish think about vaccines, health care costs, and much moreSTAT